Involvement of Plasmatic Factors in the Peripheral Muscle Dysfunction of COPD Patients - In Vitro Study

Completed

• Conditions: Chronic Obstructive Pulmonary
• Interventions: Other: Determination of pro-inflammatory plasma factors

• Registration Number: NCT03197909
• Lead Sponsor: University Hospital, Montpellier

Brief Summary

Chronic Obstructive Pulmonary Patients is a defined by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. It is associated with an atrophy of the skeletal muscle that impairs the patient's prognosis. The biological mechanisms of this muscle atrophy have not been elucidated, and the "spill-over theory" has recently emerged. Indeed, in COPD patients, the pulmonary inflammation is associated with a systemic low-grade inflammation, and the increased pro-inflamatory molelcules in the blood - which constitute the cellular micro-environement of the muscle fibre - could activate the mechanisms of the cell atrophy.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-06-21
• Study First Submitted QC: 2017-06-21
• Study First Posted: 2017-06-23
• Study Start: 2017-07-06
• Status Verified: 2018-09
• Primary Completion: 2018-12-31
• Study Completion: 2019-01-31
• Last Update Submitted: 2019-04-17
• Last Update Posted: 2019-04-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 18

Inclusion Criteria

35 to 85 years old

• COPD patients: association of symtoms (breathlessness, cough, sputum) and chronic exposure to inhalated risk factors (like tobacco smoke) and a FEV1/VC ratio <70% assessed by a spirometry
• Healthy subjects: A sedentariness assessed by a Voorrips score <9.4 and/or a report of <150 min/week of moderate-to-vigorous physical activity

Exclusion Criteria

• A recent COPD exacerbation (< 4weeks)
• The decompensation of a comorbidity
• An antioxidant supplementation or medication
• A long-term systemic corticosteroid medication

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
COPD patients	Determination of pro-inflammatory plasma factors	Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old
Healthy subjects	Determination of pro-inflammatory plasma factors	Determination of pro-inflammatory plasma factors at Healthy subjects aged from 35 to 85 years old

Primary Outcome Measures

Name	Time	Method
Myotube diameter of in vitro cultured myotubes	6 days	Myotube diameter of in vitro cultured myotubes from healthy subjects, exposed to the serum of healthy controls and COPD patients

Secondary Outcome Measures

Name	Time	Method
Expression and translation of markers of	6 days	Expression and translation of markers of anabolic and catabolic pathways

Trial Locations

Locations (1)

Uhmontpellier; 🇫🇷 Montpellier, France